1-3 of 3
Jane Tighe
Close
Sort by
Journal Articles

Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL.

Hazem A. Sayala, Paul Moreton, Ben Kennedy, Guy Lucas, Michael Leach, Saad M.B. Rassam, Andrew Haynes, Jane Tighe, David G. Oscier, Christopher Fegan, Andy C. Rawstron, Peter Hillmen
Journal: Blood
Blood (2007) 110 (11): 3114.
https://doi.org/10.1182/blood.V110.11.3114.3114
Published: 2007
Journal Articles

A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.

Nicholas Heaney, Mark Drummond, Jaspal Kaeda, Franck Nicolini, Richard Clark, George Wilson, Pat Shepherd, Jane Tighe, Lorna McLintock, Timothy Hughes, Tessa L. Holyoake
Journal: Blood
Blood (2007) 110 (11): 1033.
https://doi.org/10.1182/blood.V110.11.1033.1033
Published: 2007
Journal Articles

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

Clinical Trials & Observations
Emma Morris, Kirsty Thomson, Charles Craddock, Prem Mahendra, Donald Milligan, Gordon Cook, Graeme Murray Smith, Anne Parker, Steve Schey, Rajesh Chopra, Christopher Hatton, Jane Tighe, Anne Hunter, Karl Peggs, David Linch, Anthony Goldstone, Stephen Mackinnon
Journal: Blood
Blood (2004) 104 (13): 3865–3871.
https://doi.org/10.1182/blood-2004-03-1105
Published: 2004